REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

28/07/2017 11:05

RNS Number : 4342M
AstraZeneca PLC
28 July 2017
28 July 2017 11:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 27 July 2017, it was notified by Nazneen Rahman, a Non-Executive Director of the Company, that, on 27 July 2017, Professor Rahman purchased 500 Ordinary Shares of $0.25 each in the Company (Shares) at an aggregate price of 4338.186 pence per Share.
The Company also announces that, on 27 July 2017, it was notified by Philip Broadley, a Non-Executive Director of the Company, that, on 27 July 2017, Mr Broadley purchased 2,300 Shares at a price of 4282 pence per Share.
The attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Nazneen Rahman 
2 
Reason for the notification 
a) 
Position/status 
Non-Executive Director
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Share purchase
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
4335.4837 pence
461
4370.1282 pence
39
d) 
Aggregated information 
- Aggregated volume 
- Price 
500
4338.1860 pence
e) 
Date of the transaction 
27 July 2017
f) 
Place of the transaction 
XLON
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Philip Broadley 
2 
Reason for the notification 
a) 
Position/status 
Non-Executive Director
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Share purchase
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
4282 pence
2,300
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
27 July 2017
f) 
Place of the transaction 
XLON
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Relations


Esra Erkal-Paler
UK/Global
+44 203 749 5638
Rob Skelding
UK/Global
+44 203 749 5821
Karen Birmingham
UK/Global
+44 203 749 5634
Matt Kent
UK/Global
+44 203 749 5906
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases (CVMD)
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUWSKRBNABURR